Abstract
A new therapy for the treatment of bone metastases due to castration-resistant prostate cancer (mCRPC) is the administration of 223Ra-dichloride (223RaCl2) or 177Lu-iPSMA. Both radionuclides have a gamma emission, but the response to the treatment is not obtained by means of gammagraphic images. This evaluation is made from positron images that require a second radiopharmaceutical application to the patient as well as the appropriate installation and instrumentation. ObjectiveTo evaluate the response to treatment in bone metastases due to castration-resistant prostate cancer in patients treated with 223RaCl2 or 177Lu-iPSMA, by the uptake percentage and radiation absorbed dose in the metastatic lesion derived from gammagraphic images. MethodsTwo male patients with mCRCP received 4 and 3 cycles of 223RaCl2 and 177Lu-iPSMA, respectively. Lesion size evolution was assessed by absorbed dose calculated by MIRD methodology. Activity % was determined from gammagraphic images. ResultsTreatment with 223RaCl2 did not significantly reduce lesion size. However, the patient reported a significant reduction in pain. The patient treated with 177Lu-iPSMA showed a sustained reduction in lesion size. About 30% regression was achieved. ConclusionsThe proposed method avoids the additional use of positron radiopharmaceuticals and allows to correlate the response to treatment with the absorbed dose in the lesions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
